Custom-Made vaccine takes aim at rare childhood cancers

NCT ID NCT06094101

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a personalized peptide vaccine for children and young adults (up to age 30) with metastatic fusion-driven sarcomas (Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma) who have completed standard treatment. The vaccine is custom-made for each patient based on their tumor's unique genetic mutations. The goal is to see if the vaccine is safe and can stimulate the immune system to fight cancer cells. About 30 participants will be enrolled across multiple centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma rhabdomyosarcoma synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING SARCOMA RHABDOMYOSARCOMA SYNOVIAL SARCOMA

Contacts and locations

Locations

Pediatrics III, West German Cancer Centre, University Hospital
NOT_YET_RECRUITING

Essen, 45147, Germany
University Children's Hostpital
RECRUITING

Tübingen, 72076, Germany
Universitätsklinikum, Klinik für Kinder- und Jugendmedizin
NOT_YET_RECRUITING

Frankfurt am Main, 60590, Germany
Zentrum für Kinder- und Jugendmedizin, Universitätsklinikum
NOT_YET_RECRUITING

Freiburg im Breisgau, 79106, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.